TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CSL ( (AU:CSL) ) has shared an update.
CSL Limited announced the issuance and conversion of unquoted equity securities, specifically 11,594 ordinary fully paid shares, effective from December 1, 2025. This move is part of the company’s strategic financial operations, potentially impacting its capital structure and offering insights into its ongoing growth and investment strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, primarily focusing on the development and manufacturing of innovative biotherapies and influenza vaccines. The company is a key player in the global healthcare market, providing life-saving medicines and vaccines to patients worldwide.
Average Trading Volume: 1,197,433
Technical Sentiment Signal: Sell
Current Market Cap: A$89.09B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.